Biogen to Participate in the Stifel 2026 Virtual CNS Forum

March 10, 2026

Cambridge, MA, **- - Biogen Inc.** (Nasdaq: BIIB) announced today that Diana Gallagher, M.D., Head of Clinical Development, MS&I and AD, and Stephanie Fradette, PharmD, Head of the Neuromuscular Development Unit, will participate in a fireside chat during the Stifel 2026 Virtual CNS Forum. The webcast will be live on Wednesday, March 18, 2026, at 9:30 a.m. ET. To access the live webcast, please visit the Investors section of Biogen's website at investors.biogen.com. An archived version of the webcast will be available for at least 30 days following the presentation.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.

Contact:

Karen Jewell

Investor Relations

Biogen

781.464.2442